Balancing Aggressiveness and Conservatism
Interview with Sofie Qiao, Founder and CEO, LINQ Pharmaceuticals
439 views
00:06:24 - Uploaded by Essinova on July 27, 2011
Sofie Qiao, Ph.D. co-founded LEAD Therapeutics in 2006 on the belief of China-based innovation and a hybrid U.S.-China business model. In 2010, with two main products in preclinical development, LEAD was acquired by BioMarin Pharmaceutical, Inc., validating the company's premise and accomplishments.
With that track record in her belt, and now "older and wiser", Sofie embarked on her next venture, LINQ Pharmaceuticals.
At BioPacific 2011 organized by CABS (Chinese-American BioPharmaceutical Society), I caught up with Sofie to chat about her entrepreneurial reflections developing drugs straddling the two markets and her prospects transitioning between the two ventures.
- Host and Producer, BeiBei Song
Tags: China, drug discovery, LEAD Therapeutics, LINQ Pharmaceuticals, Sofie Qiao, CABS, BioPacific
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Discovery & Development
-
Changing Landscape of Global BioPharmaceutical Innovation and Collaboration
-
Emerging Trends and Opportunities in the BioPharmaceutical Industry in China and the US
-
Balancing Aggressiveness and Conservatism
-
US-China Anti-Cancer Association Scholar Award for Cancer Research
-
Expanding Access to Patients in Need Around the World
-
BioPacific 2010 - Drug Discovery and Development in Changing Times
-
China Drug Discovery Landscape
-
China Drug Discovery Landscape
-
Optivia Webinar - Transporter-Enzyme and Transporter-Transporter Interplay in Predicting Drug Absorption and Disposition
-
Location Determines PKC Specificity
-
KAI Selective PKC Inhibitors
-
KAI Selective PKC Activators
-
Epitomics Inc.
